[Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
We report two cases of central nervous system metastases from non-small cell lung cancer in patients being administered gefitinib, which improved after changing treatment to erlotinib. Case 1: A 57-year-old man developed carcinomatous meningitis while receiving third-line treatment with gefitinib after surgery for lung cancer. His symptoms markedly improved upon changing treatment to erlotinib. Case 2: A 54-year-old woman developed multiple brain metastases during third-line treatment with gefitinib. After changing her treatment to erlotinib, enhanced head MRI showed that the size of brain lesions had decreased. At the recommended dosage, erlotinib showed higher blood concentrations than gefitinib, and may also have been higher in cerebral spinal fluid. This may explain the difference in efficacy between gefitinib and erlotinib in central nervous system metastases.
Kunimasa
Kei
K
Department of Respiratory Medicine, Kurashiki Central Hospital.
Yoshioka
Hiroshige
H
Iwasaku
Masahiro
M
Nishiyama
Akihiro
A
Ubukata
Satoshi
S
Ishida
Tadashi
T
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology*; D016543:Central Nervous System Neoplasms / Q000556:secondary*; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib